Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, +53

The Lancet

Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineVersus Fluorouracil +7

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, +36

The Lancet Oncology

Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgical Pathology +10

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Daniel Mueller, +38

BMC Cancer

Blood‐based detection of <i><scp>RAS</scp></i> mutations to guide anti‐<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissue‐based <i><scp>RAS</scp></i> testing

Wolff Schmiegel, Rodney J. Scott, S Dooley, +33

Molecular Oncology

A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome

Burkhard Tönshoff, Lutz T. Weber, Lars Pape, +50

Kidney International

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann, +11

International Journal of Cancer

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer

Jörn Weisner, Ina Landel, Christoph Reintjes, +28

Cancer Research

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Wolff Schmiegel, A. Reinacher-Schick, Dirk Arnold, +10

Annals of Oncology

First-line TherapyMedicineCancer ManagementPharmacologyColorectal Cancer +6

Cutaneous lymphatic malformations in disappearing bone (Gorham-Stout) disease: A novel clue to the pathogenesis of a rare syndrome

D. Bruch‐Gerharz, Claus‐Dieter Gerharz, H. Stege, +4

Journal of the American Academy of Dermatology

Cutaneous Lymphatic MalformationsNovel ClueLymphatic FilariasisPathologyLymphatic Disease +4

Microalbuminuria in children with primary and white-coat hypertension

Tomáš Seeman, Michael Pohl, Daniela Palyzová, +1

Pediatric Nephrology

GlomerulonephritisHypertensionRenal FunctionMedicinePediatrics +3